Provided by Tiger Trade Technology Pte. Ltd.

Incyte

127.62
+2.872.30%
Post-market: 127.660.0400+0.03%18:45 EDT
Volume:1.47M
Turnover:186.49M
Market Cap:25.87B
PE:16.26
High:127.74
Open:125.74
Low:125.10
Close:124.75
52wk High:132.60
52wk Low:81.09
Shares:202.70M
Float Shares:169.82M
Volume Ratio:1.01
T/O Rate:0.86%
Dividend:- -
Dividend Rate:- -
EPS(TTM):7.85
EPS(LYR):6.41
ROE:30.67%
ROA:16.83%
PB:4.08
PE(LYR):19.91

Loading ...

Incyte : Bofa Global Research Raises Price Objective to $136 from $124

THOMSON REUTERS
·
Jul 15

Incyte: Early Strength in VGA039 Offsets Execution Risks; Salveen Richter Reiterates Hold and $100 Price Target

TIPRANKS
·
Jul 14

Incyte is Maintained at Overweight by Barclays

Dow Jones
·
Jul 14

Incyte: VGA039 Data Reinforces Diversification Strategy as Analyst Reiterates Hold and Keeps $103 Price Target Unchanged

TIPRANKS
·
Jul 14

Incyte price target raised to $134 from $117 at Barclays

TIPRANKS
·
Jul 14

Incyte Corp. Stock Outperforms Competitors Despite Losses on the Day

Dow Jones
·
Jul 14

Hemab Therapeutics' HMB-002 Well Suited for Type 1 Von Willebrand Disease, Wedbush Says

MT Newswires Live
·
Jul 13

Jefferies Adjusts Price Target on Incyte to $105 From $100, Maintains Hold Rating

MT Newswires Live
·
Jul 13

Incyte announces safety, efficacy data from VGA039 study

TIPRANKS
·
Jul 13

Incyte's Latarcibart Cuts Bleeding Rates in Phase 1/2 Trial in Patients With von Willebrand Disease

MT Newswires Live
·
Jul 13

Incyte - Phase 3 Vivid-6 Trial of Latarcibart for Vwd Currently Enrolling

THOMSON REUTERS
·
Jul 13

Incyte - Latarcibart Treatment Led to 81% Median Reduction in Annualized Bleeding Rate in Vwd

THOMSON REUTERS
·
Jul 13

Incyte - Presents Phase 1/2 Data for Latarcibart Showing Substantial Bleed Reductions in Vwd Patients

THOMSON REUTERS
·
Jul 13

Incyte Says Phase 1/2 Data Show 81% Median Bleed-rate Cut with VWD Drug Latarcibart

Reuters
·
Jul 13

Incyte (INCY) Could Be 8% Overvalued After Its 22% Three Month Run

Simply Wall St.
·
Jul 13

Incyte Corp. Stock Outperforms Competitors Despite Losses on the Day

Dow Jones
·
Jul 11

Does Opzelura’s EU Setback and Index Exit Reframe the Bull Case For Incyte (INCY)?

Simply Wall St.
·
Jul 10

Incyte Corp. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Jul 10

Press Release: Incyte to Report Second Quarter Financial Results

Dow Jones
·
Jul 08

Incyte Schedules Second-quarter Results Conference Call and Webcast

Reuters
·
Jul 08